Who are MenACWY-CRM197's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NeisVac-C®, NeisVac C vaccine (12mth), MenACWY-TT, Menjugate®, MCV-A vaccine, MCV4.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/menacwy-crm197.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

MenACWY-CRM197 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MenACWY-CRM197 (MenACWY-CRM197) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Meningococcal conjugate vaccine. Area: Immunology / Infectious Disease.

phase 3 Meningococcal conjugate vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

MenACWY-CRM197 (MenACWY-CRM197) — Novartis. MenACWY-CRM197 is a meningococcal conjugate vaccine that stimulates immune responses against serogroups A, C, W, and Y by conjugating polysaccharide antigens to a carrier protein (CRM197).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MenACWY-CRM197 TARGET	MenACWY-CRM197	Novartis	phase 3	Meningococcal conjugate vaccine
NeisVac-C®	NeisVac-C®	Merck Sharp & Dohme LLC	marketed	Meningococcal conjugate vaccine	Neisseria meningitidis serogroup C polysaccharide capsule
NeisVac C vaccine (12mth)	NeisVac C vaccine (12mth)	University of British Columbia	marketed	Meningococcal conjugate vaccine	Neisseria meningitidis serogroup C polysaccharide capsule
MenACWY-TT	MenACWY-TT	Pfizer	marketed	Meningococcal conjugate vaccine
Menjugate®	Menjugate®	GlaxoSmithKline	marketed	Meningococcal conjugate vaccine	Meningococcal serogroup C polysaccharide capsule
MCV-A vaccine	MCV-A vaccine	International Vaccine Institute	marketed	Meningococcal conjugate vaccine	Meningococcal serogroup A capsular polysaccharide
MCV4	MCV4	CanSino Biologics Inc.	marketed	Meningococcal conjugate vaccine	Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Meningococcal conjugate vaccine class)

GlaxoSmithKline · 8 drugs in this class
CanSino Biologics Inc. · 3 drugs in this class
Beijing Minhai Biotechnology Co., Ltd · 2 drugs in this class
Novartis · 1 drug in this class
Pfizer · 1 drug in this class
University of British Columbia · 1 drug in this class
International Vaccine Institute · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MenACWY-CRM197 — Competitive Intelligence Brief. https://druglandscape.com/ci/menacwy-crm197. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab